Subscribe to our newsletter and stay informed

Check out our list of top companies

Check out our carefully compiled lists of the most relevant and impactful companies within their fields.

Check out our list of top unicorns

Read and learn about the biggest companies that various countries have produced, how they made it, and what the future looks like for them.
January 9, 2024

Isomorphic Labs' A $3 Billion Symphony with Eli Lilly and Novartis

Isomorphic Labs teaming up with Eli Lilly and Novartis to infuse AI into the quest for medications to combat diseases

In a groundbreaking alliance at the nexus of technology and healthcare, Isomorphic Labs, the London-based drug discovery powerhouse born from Google AI R&D division DeepMind, has unveiled strategic partnerships with pharmaceutical titans Eli Lilly and Novartis. This symphony of collaboration, with a combined value soaring to $3 billion, signals a futuristic approach to medication discovery, blending cutting-edge AI technologies with pharmaceutical expertise.

Isomorphic Labs stands at the forefront, having sealed deals with Eli Lilly and Novartis, each laden with promise and innovation. Eli Lilly's commitment includes a substantial upfront payment of $45 million, coupled with the potential to soar up to $1.7 billion based on performance milestones, sans royalties. Novartis, on the other hand, enters the fray with a $37.5 million initial investment, covering select research costs and offering performance-based incentives climbing to a staggering $1.2 billion over time.

Isomorphic's CEO, Demis Hassabis, expressed enthusiasm, stating, “We’re thrilled to embark on this partnership and apply our proprietary technology platform." The collaboration aligns with a shared focus on advancing groundbreaking drug design approaches and a deep appreciation for state-of-the-art science, making these partnerships particularly compelling.

Novartis President of Biomedical Research, Fiona Marshall, emphasized the transformative potential of cutting-edge AI technologies in drug discovery. The collaboration aims to harness the unique strengths of both entities, merging AI and data science with medicinal chemistry and deep disease area expertise to unlock new horizons in AI-driven drug discovery.

Isomorphic draws its prowess from DeepMind's AlphaFold 2 AI technology, designed by Demis Hassabis in 2021. This technology predicts protein structures within the human body, laying the groundwork for identifying target pathways crucial in developing disease-fighting drugs.

While acknowledging that AlphaFold is not flawless, researchers have successfully utilized it to design a potential drug for hepatocellular carcinoma, the most common form of primary liver cancer. Beyond profits, Isomorphic is extending its reach by collaborating with the Drugs for Neglected Diseases initiative to combat Chagas disease and Leishmaniasis, deadly diseases in the developing world.

As Isomorphic Labs embarks on this pioneering journey with Eli Lilly and Novartis, the fusion of AI and pharmaceutical expertise heralds a new era in drug discovery. The potential to transform hypotheses into life-changing medicines beckons, with Isomorphic applying the latest AlphaFold model to navigate molecular structures vital for disease treatment. Amid the quest for profitability, Isomorphic's commitment to pushing scientific boundaries positions it as a key player in reshaping the future of pharmaceutical innovation. The stage is set, the partnerships forged, and as Isomorphic steps into the limelight, the world awaits the crescendo of breakthroughs in AI-driven drug discovery.

Josefina Dipaolo
Josefina Dipaolo
Content writer at TechNews180
Back to top

Related articles

chevron-down linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram